Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 14/20 | 0.65 |
| ▸ | NT5E | P21589 | 1/20 | 0.64 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.63 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.57 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.57 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23907385 | 0.89 | ADORA3 (0.71) | DNPH1ADORA3NT5EP2RX3P2RX2 | |
| SCHEMBL23907467 | 0.88 | DNPH1 (0.68) | DNPH1ADORA3NT5EP2RX3P2RX2 | |
| SCHEMBL21839668 | 0.88 | DNPH1 (0.69) | DNPH1ADORA3NT5EP2RX3P2RX2 | |
| SCHEMBL23907411 | 0.86 | ADORA3 (0.70) | DNPH1ADORA3NT5EP2RX3P2RX2 | |
| SCHEMBL23907437 | 0.85 | P2RX3 (0.62) | DNPH1ADORA3NT5EP2RX3P2RX2 | |
| SCHEMBL23907409 | 0.85 | DNPH1 (0.64) | DNPH1ADORA3NT5EP2RX3P2RX2 | |
| SCHEMBL23907510 | 0.84 | P2RX3 (0.64) | DNPH1ADORA3NT5EP2RX3P2RX2 | |
| SCHEMBL23907433 | 0.83 | P2RX3 (0.61) | DNPH1NT5EP2RX3P2RX2ADORA1 | |
| SCHEMBL14689156 | 0.83 | DNPH1 (0.82) | DNPH1ADORA3NT5EP2RX3P2RX2 | |
| SCHEMBL23907460 | 0.82 | DNPH1 (0.78) | DNPH1NT5EP2RX3P2RX2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | DNPH1 1090/4885ADORA3 9/4885NT5E 5/4885 |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | DNPH1 297/4885ADORA3 29/4885NT5E 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.